Beijing Tiantan Biological Products 미래 성장

Future 기준 확인 2/6

Beijing Tiantan Biological Products (는) 각각 연간 19.7% 및 19.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 20.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14% 로 예상됩니다.

주요 정보

19.7%

수익 성장률

20.6%

EPS 성장률

Biotechs 수익 성장	43.6%
매출 성장률	19.6%
향후 자기자본 수익률	14.0%
애널리스트 커버리지	Good
마지막 업데이트	06 Nov 2024

최근 미래 성장 업데이트

Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Oct 29

Recent updates

Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Oct 29

Beijing Tiantan Biological Products (SHSE:600161) Ticks All The Boxes When It Comes To Earnings Growth

Oct 27

Calculating The Fair Value Of Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161)

Oct 08

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Shares May Have Run Too Fast Too Soon

Sep 19

Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?

Jul 23

Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value

Jun 09

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings

May 22

We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Mar 16

Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?

Mar 01

수익 및 매출 성장 예측

SHSE:600161 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	8,211	1,975	1,820	2,459	8
12/31/2025	7,131	1,648	1,589	2,510	7
12/31/2024	5,928	1,361	1,082	1,160	3
9/30/2024	5,232	1,274	270	1,351	N/A
6/30/2024	5,331	1,269	1,183	2,328	N/A
3/31/2024	5,110	1,165	1,087	2,242	N/A
12/31/2023	5,180	1,110	1,316	2,394	N/A
9/30/2023	5,371	1,167	1,254	2,515	N/A
6/30/2023	5,062	1,063	341	1,633	N/A
3/31/2023	4,848	1,018	250	1,539	N/A
12/31/2022	4,261	881	-228	1,126	N/A
9/30/2022	4,207	803	-195	1,097	N/A
6/30/2022	4,191	808	-187	1,117	N/A
3/31/2022	3,970	733	-351	918	N/A
12/31/2021	4,112	760	-151	980	N/A
9/30/2021	3,628	700	-241	728	N/A
6/30/2021	3,702	692	-120	640	N/A
3/31/2021	3,535	659	-71	571	N/A
12/31/2020	3,446	639	93	702	N/A
9/30/2020	3,398	641	306	755	N/A
6/30/2020	3,276	601	362	877	N/A
3/31/2020	3,334	611	184	741	N/A
12/31/2019	3,282	611	116	642	N/A
9/30/2019	3,394	580	282	788	N/A
6/30/2019	3,271	563	376	801	N/A
3/31/2019	3,083	531	729	1,028	N/A
12/31/2018	2,931	509	384	678	N/A
9/30/2018	2,929	568	538	767	N/A
6/30/2018	2,671	532	N/A	590	N/A
3/31/2018	2,485	1,228	N/A	186	N/A
12/31/2017	2,483	1,173	N/A	138	N/A
9/30/2017	2,362	1,077	N/A	301	N/A
6/30/2017	2,256	1,038	N/A	280	N/A
3/31/2017	2,330	313	N/A	344	N/A
12/31/2016	2,138	257	N/A	433	N/A
9/30/2016	1,756	151	N/A	251	N/A
6/30/2016	1,709	55	N/A	403	N/A
3/31/2016	1,624	-3	N/A	471	N/A
12/31/2015	1,618	10	N/A	473	N/A
9/30/2015	1,545	-88	N/A	384	N/A
6/30/2015	1,567	-46	N/A	382	N/A
3/31/2015	1,723	46	N/A	560	N/A
12/31/2014	1,827	128	N/A	478	N/A
9/30/2014	2,026	291	N/A	748	N/A
6/30/2014	2,018	377	N/A	705	N/A
3/31/2014	1,905	371	N/A	490	N/A
12/31/2013	1,837	372	N/A	566	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 600161 의 연간 예상 수익 증가율( 19.7% )이 saving rate( 2.8% 보다 높습니다. ).

수익 vs 시장: 600161 의 연간 수익( 19.7% ) CN 시장( 26% 보다 느리게 성장할 것으로 예상됩니다. 26% 연간).

고성장 수익: 600161 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 600161 의 수익(연간 19.6% ) CN 시장( 13.9% 보다 빠르게 성장할 것으로 예상됩니다. 13.9% 연간).

고성장 수익: 600161 의 수익(연간 19.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 600161 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 14 %).

Beijing Tiantan Biological Products 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Price target increased by 11% to CN¥33.90

Recent updates

Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Beijing Tiantan Biological Products (SHSE:600161) Ticks All The Boxes When It Comes To Earnings Growth

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Dividend sustainability

Calculating The Fair Value Of Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161)

Beijing Tiantan Biological Products Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 23%

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Shares May Have Run Too Fast Too Soon

Second quarter 2024 earnings: EPS misses analyst expectations

Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Investor sentiment deteriorates as stock falls 20%

Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued after recent price rise

Price target increased by 11% to CN¥33.90

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings

Now 21% overvalued after recent price rise

Now 27% overvalued

Full year 2023 earnings: EPS and revenues miss analyst expectations

Beijing Tiantan Biological Products Co., Ltd., Annual General Meeting, May 29, 2024

We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.67 (vs CN¥0.53 in FY 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.14 in 3Q 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.075 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) dropped from S&P Global BMI Index

Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) dropped from FTSE All-World Index (USD)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 3Q 2021)

Now 20% undervalued

Second quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.12 in 2Q 2021)

Now 20% undervalued

Now 21% undervalued

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.12 in 2Q 2021)

Now 24% undervalued after recent price drop

Less than half of directors are independent

Now 20% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.17 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 2Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 1Q 2020)

New 90-day low: CN¥36.46

Investor sentiment deteriorated over the past week

New 90-day high: CN¥42.50

New 90-day high: CN¥41.95

Beijing Tiantan Biological Products Co., Ltd. announced that it expects to receive CNY 3.34 billion in funding

Third quarter earnings released

New 90-day low: CN¥37.99

First half earnings released

First half earnings released

New 90-day high - CN¥42.80

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견